Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Will Acquire Generics Rival Barr

July 28, 2008 | A version of this story appeared in Volume 86, Issue 30

Jerusalem-based Teva Pharmaceutical Industries, the world's largest generic drug company, has agreed to purchase Barr Pharmaceuticals of Montvale, N.J., the fourth largest generics firm, for $7.5 billion plus the assumption of $1.5 billion in debt. Expected to close later this year, the deal will create a company with pro forma sales of $11.9 billion and 37,000 employees in 60 countries. Teva and Barr primarily are generics firms, but both also have proprietary drugs. Copaxone, an immunomodulator therapy for relapsing-remitting multiple sclerosis, represents more than 50% of Teva's U.S. sales. "The deal reflects growing opportunities in emerging markets," says Eric Snyder, an analyst with Mehta Partners. He notes that the acquisition follows Daiichi Sankyo's $4.6 billion bid for India's Ranbaxy Laboratories last month, and Barr's acquisition of Pliva, a Croatian generics firm, for $2.2 billion in 2006. Meanwhile, the board of Prague-based generics firm Zentiva has recommended that shareholders not accept a $2.5 billion takeover offer from Sanofi-Aventis, claiming that it undervalues the company.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.